Following the records, we can see that the recent price jump happened after Coldwater announced its improved financial results for the second quarter of this year. According to the report, the company has increased its revenue and gross profit, though it has incurred a net loss of approximately $5 million. This year, Coldwater opened five new premium retail stores, however, its cash decreased and the expenses totaled $169 million.

Though the losses, the company expects to gain future profit and projects earnings per share in the range of $0.01 to $0.04 for the third quarter of this year. Yesterday, Coldwater Creek was to host a conference call on its financial results, however there’s no further news on this issue yet.

Coldwater Creek Inc. is a national specialty retailer of women apparel, accessories, jewelry and gift items sold under the Coldwater Creek brand. Historically, the company used to trade about 50% higher, though since April, this year, the stock entered a downtrend. After the high trade yesterday, it is falling down again, so the only question now is what’s the next move of CWTR? It’s just up to be seen.

According to the press release, Marlin will acquire all outstanding shares of Phoenix common stock for $3.85 per share and the board of directors of Phoenix has already approved the cash transaction.

Looks like after reporting the news, the investors got interested in PTEC and the stock soared over 25% on its price. Along with the price jump, its traded volume exceeded the unusual 20 million shares. That’s a phenomenal value for Phoenix and it immediately placed it among the largest volume increases on NASDAQ.

But what’s going to happen after the big climb?

The latest financial results of PTEC show that its net income and gross profit are a bit lower as compared to the previous period and the company still has a net loss to cover. The good news for Phoenix is that it has more assets than liabilities on its balance sheet and no long-term debt.

Presently, the company is hopeful about its new agreement with Marlin and relies mainly on its financial resources. However, no one knows what’s to follow after the investigation of the Board is closed.

What’s behind the stock’s high momentum then?

Apparently, that’s the news that ICGN won’t be delisted from NASDAQ at least by November, this year. According to Triangle Business Journal, “Nasdaq has granted the company’s request for more time to regain compliance with the $1.00 per share minimum bid price requirement”. Though, Icagen can not guarantee it will be able to reach the minimum price.

Still, last week, the company released another good news on receiving a $3 million milestone payment from Pfizer. Probably, that has impressed the investors, as currently, the stock still moves up.

Icagen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. Historical data shows that last year the company used to trade at over $1 per share, though after that the price fell down.

The ICGN’s first quarter results for this year point that its revenue and gross profit have increased, though it has suffered a net loss. According to the financial report, the company still has more assets than liabilities on its balance sheet, which should be sufficient to cover its current operations. However, ICGN stated that: “A substantial portion of our revenue for at least the next several years will depend on our achieving development and regulatory milestones in our existing collaborative research and development program and entering into new collaborations.”

Icagen claimed that it would need additional funds to meet its obligations and fund operations beyond the third quarter of 2010, and announced that its second quarter results are to be reported on 10 August.

What’s behing the present move? It should be the positive announcements along with the optimistic projections, released by AMPE over the last days. Could be these, that made the investors start buying, though the news is related to the future and the high expectations cannot be confirmed yet.

Ampio Pharmaceuticals develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. According to the historical data, AMPE has traded much higher during the last 6 months, when its price reached $4.05 per share. However, there was a shocking price crash in June, this year. After that the stock has had frequent ups and downs to start moving up again. Still, its too soon an uptrend to be recorded.

The quarterly results of AMPE look disappointing. They point that the company has not generated any revenue so far, and it has suffered higher expenses. AMPE still has some cash on hand, though its operating loss has increased.

In its 2010 quarterly report, Ampio states that its: “Cash equivalents consist primarily of money market investments”, and that the company needs to raise additional capital to complete its business plan.

Based on these facts, traders should carefully observe the future movement of the AMPE stock.

Presidents changed but the business model remains the same, even though it proved to be ineffective. Well, at least their balance sheet looks good with the $1.5 million in “investments” that auditors didn’t check.

0.0001 fluctuations still kick in, but the volume should eventually set down and in turn the price would go flat once again. For those considering it can only go up from here - this might not be the end after all. There is still 75% drop to the $0.0001 line and some more reverse splits from there on, just like in the past half a year when the share count went from 250M to 14M. This stock is for gambling addicts only!

The company has no recent press releases on its website and hasn’t made any general announcements during the last months. However, the records show that BYSD has paid 200k free trading shares to get promoted, which may explain the sudden volume jump.

The promoters can sell their shares right after the promotion, though in the BYSD case the price was probably artificially inflated. But still, we can find no definite explanation on the downtrend, which occurred. We can only assume the promoter has failed and decided to sell all the shares of BYSD.

Though the company’s revenue for 2009 was lower than the year before, its sales have increased. Last year KKD’s cash flow from operating activities rose up, while its general and administrative expenses dropped.

After the company announced its double earnings, shares in Krispy Kreme were up 6.2 percent. On Friday the market closed at 3.94, and the traded volume exceeded 1 million shares. Today KKD stock reached 4.02 at market cap of 267.74M.

Krispy Kreme is satisfied with the improvement in its first quarter performance and expects a 2011 operating income from $11 million to $15 million.

The company is working to provide better support for its franchise partners and shareholders and publishes all the news on its projects on the Krispy Kreme’s official website.

After the news was reported, LNG’s stock flew up 12.69% at 3.02 on the high volume of over 1 million shares. It is more than the company’s average traded volume and it still keeps a high value.

During the last weeks, there was a resistance level at 3.0, while currently LNG trades at 3.34 and the maket cap points 191.26M.

Cheniere Energy, Inc. is developing a platform of three, 100%-owned, onshore liquefied natural gas, or LNG, receiving terminals along the U.S. Gulf Coast. According to the records, company’s revenue for 2009 is higher than the year before, but its net income is 2 times lower. However, the LNG’s quarterly results for 2010 look better.

Although the results were consolidated for financial reporting, Cheniere, Sabine Pass LNG, L.P. and Cheniere Partners operate with independent capital structures. In March 2010, Cheniere Marketing entered into an agreement with JPMorgan LNG Co., providing financial support to source more cargoes of LNG than it could source on a stand-alone basis. The next month, the company sold a 30% interest in Freeport LNG, which improved its liquidity and capital positions.

Currently, LNG continues to be involved in oil and gas exploration and believes they have sufficient cash to accomplish the company’s business plan until its debt begins to mature in August 2011.

As a result of the news, DPTR stock moved up on the market. Yesterday it plunged by 6.09% and closed at $1.22 at market cap 345.00M. The traded volume of DPTR also rose up and exceeded 5 million shares.

Delta Petroleum is an independent oil gas exploration and production company. It holds 49.8% of contract driller DHS Holding and has oil and gas leasehold properties covering approximately 893 thousand undeveloped acres.

The results from Delta’s quarterly report for 2010 show that oil and gas sales increased 55%, but the company reported a net loss attributable to common stockholders of $12.8 million. However, if the present uptrend continues, it will bring higher profit to DPTR.

After this announcement was made, Generex’s shares rose up 5.47% and the market cap became 106.99M. Yesterday the stock closed at $0.42 with total volume of 4.27 million traded shares.

Though Generex Biotechnology Corp. has lost over 11% during the past month, it is currently trading above its 20-day and below its 50-day moving averages.

The company’s financials show that its revenue and net income for 2009 are higher compared to 2008, and the employee growth points 59.3%.

This year GNBT expects the new patents will bring higher profit to its business. At the company’s official website, Generex publishes the news on its projects, as well as a letter to the shareholders with all the information on GNBT’s products and approvals.